Global Liquid Biopsy Market, By Sampling Type (Blood Sampling Liquid Biopsy, Urine Sampling Liquid Biopsy, and Saliva and Other Tissue Fluids Sampling Liquid Biopsy), Products and Services (Assays Kits, Instruments and Services), Circulating Biomarker (Circulating Tumour Cells, Circulating Tumour DNA (CTDNA), Cell-Free DNA, Extracellular Vesicles (EVS) and Other Circulating Biomarkers), Clinical Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, and Recurrence Monitoring), Application (Cancer Applications and Non-Cancer Applications), End User (Reference Laboratories, Hospitals, and Physician Laboratories, Academic and Research Centres and Other End Users) – Industry Trends and Forecast to 2030.
Liquid Biopsy Market Analysis and Size
Increasing lab-related research and development activities directly influence the market's growth. Liquid biopsy has gained a huge attraction, particularly in western economies, as a non-invasive alternative technique. Governments in numerous countries and health organizations have undertaken some initiatives to spread cancer awareness, instigating the use of liquid biopsy. It has been observed that the circulating tumor DNA segment held a large revenue share in 2021 to the liquid biopsy market revenue.
Data Bridge Market Research analyses that the liquid biopsy market, which was USD 3.30 billion in 2022, would rise to USD 14.11 billion by 2030 and is expected to undergo a CAGR of 21.20% during the forecast period from 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Liquid Biopsy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Service Type (HCIT Strategy and Project/Program Management, Healthcare Application Analysis, Design, and Development, HCIT Integration and Migration, HCIT Change Management, Healthcare/Medical System Security Set-Up and Risk Assessment, Healthcare Enterprise Reporting and Data Analytics, Production Go-Live/ Post Go-Live Support, Healthcare Business Process Management, Regulatory Compliance, Others), End Users (Healthcare Providers, Healthcare Payer, Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics, Inc. (U.S.), QIAGEN (Netherlands), Thermo Fisher Scientific. (U.S.), MDxHealth SA (Belgium), Exact Sciences Corporation (U.S.), Illumina Inc. (U.S.), Sysmex Inostics (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Biocept, Inc. (U.S.), NeoGenomics, Inc. (U.S.), Vortex Biosciences, Inc. (U.S.), Exosome Diagnostics, Inc. (U.S.), Agena Bioscience, Inc. (U.S.), MedGenome Inc. (U.S.), Epigenomics AG (Germany), and Personal Genome Diagnostics, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Liquid biopsy is a non-invasive and fast technology in which blood is drawn from the patient body. It is also known as fluid biopsy, performed to diagnose cancer cells that lead to a tumor circulating in the bloodstream. Liquid biopsy is meant to detect and diagnose cancer at an early stage. Liquid biopsies provide a much less invasive substitute than a traditional tissue biopsies.
Global Liquid Biopsy Market Dynamics
Drivers
- Increasing Strategic Initiatives for Liquid Biopsy
There have been many strategic initiatives by organizations for a liquid biopsy that push market growth. For instance, NeoGenomics, Inc. launched a mobile phlebotomy service for liquid biopsy tests, including NeoLAB and InvisionFirst, in 2020. The company provides its service through two phlebotomy companies, ExamOne and Metro Health Staffing LLC, covering a large area to ensure the tests are performed efficiently. Thus, this factor boosts market growth.
- Increasing Technological Advancements by Market Players
The major market players have launched innovative products, boosting the market growth. For instance, Twist Bioscience Corp. launched Twist NGS Methylation Detection System for liquid biopsy cancer analysis and epigenetic studies in 2021. In addition, Biodesix, Inc. announced its plan to launch a blood-based 52-gene NGS test to improve its portfolio of molecular testing in 2021. Thus, all these technological advancements enhance market growth.
Opportunities
- Increasing R&D Activities by Institutes
Several scientists are performing more research on liquid biopsy that assists in the market growth. Scientists from Cornell University are developing a liquid biopsy test that helps detect and measure injury to cells, tissue, and organs because of COVID-19. The test measures the severity of the disease and projects its outcomes. In addition, it can show the involvement of numerous organs in disorder. This is anticipated to surge R&D funding, further boosting the market growth.
- Growing Demand for PCR
PCR seems to be in great demand in recent times. The adoption of PCR is increasing due to its enormous uses for many purposes, such as detecting bacterial infections, fungal infections, gene mapping, and other genomic applications. The quick and real-time diagnostic results offered by the PCR tests are accurate and can assist the targeted therapies for cancer treatment. PCR is gaining huge popularity and is anticipated to grow considerably in the upcoming year. Thus, it is helping in the market growth.
Restraints/Challenges
- High Cost Associated with Liquid Biopsy
An increased cost is associated with expensive equipments, research tools, chemicals, and maintenance. Increasing expenditure for research and development activities particularly in the developed and developing economies associated with medical instruments and devices, will create huge market growth opportunities. Thus, this acts as a major factor in the market hindrance.
- Increased Dependency on Other Biopsies
One major disadvantage of liquid biopsy is that it necessitates an initial histologic diagnosis that is to be obtained by tissue biopsy. Assays for ctDNA do not offer any information into many important tumor properties for grading and staging; instead, indirectly suggest overall tumor burden. Thus, this factor impedes market growth.
This liquid biopsy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the liquid biopsy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
• In 2021, BioMark Diagnostic Solutions, Inc. gained USD 825,000 in funding to develop BioMark's liquid biopsy assay for screening lung cancer. A major part of the funding is being issued by the Consortium for Industrial Research and Innovation in Medical Technology and Spark grants from the Canadian Cancer Society, Canadian Institutes of Health Research - Institute of Cancer Research, and Brain Canada Foundation.
Global Liquid Biopsy Market Scope
The liquid biopsy market is segmented on the basis of sampling type, product and service, circulating biomarker, clinical application, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Sampling Type
- Blood Sampling
- Urine Sampling
- Saliva
- Other Tissue Fluids Sampling Liquid Biopsy
Products and Services
- Assays Kits
- Instruments and Services
Circulating Biomarker
- Circulating Tumour Cells
- Circulating Tumour DNA (CTDNA)
- Cell-Free DNA, Extracellular Vesicles (EVS)
- Other Circulating Biomarkers
Clinical Application
- Early Cancer Screening
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring
Application
- Cancer Applications
- Non-Cancer Applications
End User
- Reference Laboratories
- Hospitals and Physician Laboratories
- Academic and Research Centres
- Other End Users
Liquid Biopsy Market Regional Analysis/Insights
The liquid biopsy market is analyzed and market size insights and trends are provided by sampling type, product and service, circulating biomarker, clinical application, application and end user as referenced above.
The countries covered in the liquid biopsy market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the liquid biopsy market because of the strong base of healthcare facilities, increasing investment from major market players in the growth of the advanced devices. Also, rising number of processes associated with drug development, and higher number of research activities in this region increase the market growth.
Asia-Pacific is expected to witness significant growth due to the rise in government initiatives to promote awareness, increase in medical tourism, rising research activities in the region, growing cancer cases, and the increasing demand for quality healthcare.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The liquid biopsy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for liquid biopsy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the liquid biopsy market. The data is available for historic period 2011-2021.
Competitive Landscape and Liquid Biopsy Market Share Analysis
The liquid biopsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to liquid biopsy market.
Some of the major players operating in the liquid biopsy market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Myriad Genetics, Inc. (U.S.)
- QIAGEN (Netherlands)
- Thermo Fisher Scientific. (U.S.)
- MDxHealth SA (Belgium)
- Exact Sciences Corporation (U.S.)
- Illumina Inc. (U.S.)
- Sysmex Inostics (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Biocept, Inc. (U.S.), NeoGenomics, Inc. (U.S.)
- Vortex Biosciences, Inc. (U.S.)
- Exosome Diagnostics, Inc. (U.S.)
- Agena Bioscience, Inc. (U.S.)
- MedGenome Inc. (U.S.)
- Epigenomics AG (Germany)
- Personal Genome Diagnostics, Inc. (U.S.)
SKU-